LAD603

DRUG3 trials

Sponsors

Almirall S.A., Almirall, S.A.

Conditions

Alopecia AreataAlopecia areataHealthy Volunteers

Phase 1

A Single and Multiple Ascending Dose Study of LAD603 in Healthy Subjects

CompletedNCT06200597

Almirall, S.A.Healthy Volunteers

Start: 2023-12-05End: 2025-05-29Updated: 2025-12-17

Phase 2

A Study of LAD603 in Adults With Alopecia Areata

RecruitingNCT07311564

Almirall, S.A.Alopecia Areata

Start: 2025-12-17End: 2027-11-21Target: 136Updated: 2026-05-20

A Phase 2, randomized, placebo-controlled, double-blind clinical study to evaluate efficacy and safety of LAD603 in adult subjects with severe to very severe alopecia areata

Not yet recruitingCTIS2025-523342-27-00

Almirall S.A.Alopecia areata

Target: 70Updated: 2026-03-25